BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31419753)

  • 1. Clinical and genetic analysis of melanomas arising in acral sites.
    Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
    Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Genomic Profiling of Acral Melanoma.
    Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
    J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.
    Rawson RV; Johansson PA; Hayward NK; Waddell N; Patch AM; Lo S; Pearson JV; Thompson JF; Mann GJ; Scolyer RA; Wilmott JS
    Lab Invest; 2017 Feb; 97(2):130-145. PubMed ID: 28067894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
    Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
    Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
    Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    Moon KR; Choi YD; Kim JM; Jin S; Shin MH; Shim HJ; Lee JB; Yun SJ
    J Invest Dermatol; 2018 Apr; 138(4):933-945. PubMed ID: 29191620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutation is uncommon in acral lentiginous melanoma.
    Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
    J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.
    Millan-Esteban D; García-Casado Z; Macià A; de la Rosa I; Torrecilla-Vall-Llossera C; Penin RM; Manrique-Silva E; Pellegrini S; Biasin MR; Rizzolo P; Gavillero A; Di Stefani A; Pellegrini C; Requena C; Fargnoli MC; Peris K; Cota C; Menin C; Landi MT; Nagore E
    Dermatology; 2024; 240(1):164-169. PubMed ID: 37918362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
    J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.